-
Something wrong with this record ?
Ovarian mesonephric-like adenocarcinoma arising in serous borderline tumor: a case report with complex morphological and molecular analysis
P. Dundr, M. Gregová, K. Němejcová, M. Bártů, N. Hájková, J. Hojný, I. Stružinská, D. Fischerová
Language English Country Great Britain
Document type Case Reports, Journal Article
Grant support
AZV NV19-03-00007
Ministerstvo Zdravotnictví Ceské Republiky
RVO 64165
Ministerstvo Zdravotnictví Ceské Republiky
Progress Q28/LF1
Univerzita Karlova v Praze
UNCE204065
Univerzita Karlova v Praze
CZ.02.1.01/0.0/0.0/18_046/0015959
European Regional Development Fund
BBMRI_CZ LM2018125
European Regional Development Fund
OPPK - Research Laboratory of Tumor Diseases, CZ.2.16/3.1.00/24509
European Regional Development Fund
NLK
BioMedCentral
from 2006-12-01
BioMedCentral Open Access
from 2006
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
Springer Nature OA/Free Journals
from 2006-12-01
- MeSH
- Adenocarcinoma diagnosis pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Mesonephroma pathology MeSH
- Biomarkers, Tumor analysis MeSH
- Uterine Neoplasms diagnosis pathology MeSH
- Ovarian Neoplasms diagnosis pathology MeSH
- Ovary pathology MeSH
- Precancerous Conditions pathology MeSH
- Cystadenoma, Serous diagnosis pathology MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
BACKGROUND: Mesonephric-like adenocarcinoma (M-LAC) is a rare, recently described tumor occurring in the uterine corpus and ovary, which shares the same morphological and immunohistochemical features with the more common mesonephric adenocarcinoma (MAC), which mostly arises the uterine cervix. Despite the similarities between these tumors, the histogenesis of M-LAC is still disputable. CASE PRESENTATION: Sixty-one-year-old woman presented with an advanced tumor of the left ovary with intraabdominal spread and liver metastases. After receiving 5 cycles of neoadjuvant chemotherapy, she underwent a hysterectomy with bilateral salpingo-oophorectomy, and resection of the liver metastasis, omentum, and appendix. Histologically, the ovarian tumor consisted of two components, whose morphology and immunohistochemical results were typical of either a serous borderline tumor (immunohistochemical positivity for PAX8, WT1, ER and PR) or a mesonephric-like carcinoma (immunohistochemical positivity for PAX8, TTF1 and GATA3). Only the component of the mesonephric-like adenocarcinoma metastasized to the omentum and liver. A molecular analysis with a panel of 271 genes (size 1020 kbp) was performed separately on samples from the borderline tumor, primary ovarian mesonephric-like adenocarcinoma, and liver metastasis. The results showed the clonal origin of all samples, which shared the same KRAS (NM_004985.3:c.34G > T, p.(G12C)) and PIK3CA (NM_006218.2:c.1633G > A, p.(E545K)) somatic mutations. Moreover, in the sample from the primary mesonephric-like carcinoma and its liver metastasis a likely pathogenic somatic MYCN mutation (NM_005378.4:c.131C > T, p.(P44L) was found. In all samples, the deletion of exons 9-10 in the CHEK2 gene was present, which is in concordance with the previously performed genetic testing of the blood specimen which revealed the hereditary CHEK2 mutation in this patient. CONCLUSIONS: Our result support the theory that at least some mesonephric-like ovarian adenocarcinomas are of Müllerian origin. The serous borderline tumor seems to be a precursor of mesonephric-like adenocarcinoma, which has been proven in our case by both tumors sharing the same mutations, and the presence of cumulative molecular aberrations in the mesonephric-like adenocarcinoma.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020345
- 003
- CZ-PrNML
- 005
- 20210830102045.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13000-020-01012-z $2 doi
- 035 __
- $a (PubMed)32693840
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz
- 245 10
- $a Ovarian mesonephric-like adenocarcinoma arising in serous borderline tumor: a case report with complex morphological and molecular analysis / $c P. Dundr, M. Gregová, K. Němejcová, M. Bártů, N. Hájková, J. Hojný, I. Stružinská, D. Fischerová
- 520 9_
- $a BACKGROUND: Mesonephric-like adenocarcinoma (M-LAC) is a rare, recently described tumor occurring in the uterine corpus and ovary, which shares the same morphological and immunohistochemical features with the more common mesonephric adenocarcinoma (MAC), which mostly arises the uterine cervix. Despite the similarities between these tumors, the histogenesis of M-LAC is still disputable. CASE PRESENTATION: Sixty-one-year-old woman presented with an advanced tumor of the left ovary with intraabdominal spread and liver metastases. After receiving 5 cycles of neoadjuvant chemotherapy, she underwent a hysterectomy with bilateral salpingo-oophorectomy, and resection of the liver metastasis, omentum, and appendix. Histologically, the ovarian tumor consisted of two components, whose morphology and immunohistochemical results were typical of either a serous borderline tumor (immunohistochemical positivity for PAX8, WT1, ER and PR) or a mesonephric-like carcinoma (immunohistochemical positivity for PAX8, TTF1 and GATA3). Only the component of the mesonephric-like adenocarcinoma metastasized to the omentum and liver. A molecular analysis with a panel of 271 genes (size 1020 kbp) was performed separately on samples from the borderline tumor, primary ovarian mesonephric-like adenocarcinoma, and liver metastasis. The results showed the clonal origin of all samples, which shared the same KRAS (NM_004985.3:c.34G > T, p.(G12C)) and PIK3CA (NM_006218.2:c.1633G > A, p.(E545K)) somatic mutations. Moreover, in the sample from the primary mesonephric-like carcinoma and its liver metastasis a likely pathogenic somatic MYCN mutation (NM_005378.4:c.131C > T, p.(P44L) was found. In all samples, the deletion of exons 9-10 in the CHEK2 gene was present, which is in concordance with the previously performed genetic testing of the blood specimen which revealed the hereditary CHEK2 mutation in this patient. CONCLUSIONS: Our result support the theory that at least some mesonephric-like ovarian adenocarcinomas are of Müllerian origin. The serous borderline tumor seems to be a precursor of mesonephric-like adenocarcinoma, which has been proven in our case by both tumors sharing the same mutations, and the presence of cumulative molecular aberrations in the mesonephric-like adenocarcinoma.
- 650 _2
- $a adenokarcinom $x diagnóza $x patologie $7 D000230
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 _2
- $a serózní cystadenom $x diagnóza $x patologie $7 D018293
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mezonefrom $x patologie $7 D008649
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory vaječníků $x diagnóza $x patologie $7 D010051
- 650 _2
- $a ovarium $x patologie $7 D010053
- 650 _2
- $a prekancerózy $x patologie $7 D011230
- 650 _2
- $a nádory dělohy $x diagnóza $x patologie $7 D014594
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gregová, Mária $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Hájková, Nikola $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Fischerová, Daniela $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Apolinarska 18, 12808, Prague 2, Czech Republic
- 773 0_
- $w MED00165474 $t Diagnostic pathology $x 1746-1596 $g Roč. 15, č. 1 (2020), s. 91
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32693840 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102045 $b ABA008
- 999 __
- $a ok $b bmc $g 1691007 $s 1140791
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 15 $c 1 $d 91 $e 20200721 $i 1746-1596 $m Diagnostic pathology $n Diagn Pathol $x MED00165474
- GRA __
- $a AZV NV19-03-00007 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO 64165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a Progress Q28/LF1 $p Univerzita Karlova v Praze
- GRA __
- $a UNCE204065 $p Univerzita Karlova v Praze
- GRA __
- $a CZ.02.1.01/0.0/0.0/18_046/0015959 $p European Regional Development Fund
- GRA __
- $a BBMRI_CZ LM2018125 $p European Regional Development Fund
- GRA __
- $a OPPK - Research Laboratory of Tumor Diseases, CZ.2.16/3.1.00/24509 $p European Regional Development Fund
- LZP __
- $a Pubmed-20210728